Characterization of JAK1 and JAK2 Activation in Gingival Tissues During Homeostasis and Periodontitis

April 10, 2026 updated by: University of Chile

Unraveling the Role of JAK1 and JAK2 Pathway in Periodontitis: Drivers of Immunopathology and Possible Therapeutic Targets

The goal of this observational study is to examine JAK1/2 pathway activation in gingival tissues from adults with healthy gingiva and those with inflamed gingiva (periodontitis). The main question it aims to answer is:

Is the JAK1/2 pathway overactivated in periodontitis compared to health?

Participants with healthy gingiva and periodontitis will donate gingival tissue to study the JAK1/2 pathway. All participants wil receive diagnosis and treatment of the gingival condition.

Study Overview

Status

Recruiting

Conditions

Detailed Description

The goal of this observational study is to examine JAK1/2 pathway activation in gingival tissues from adults with healthy gingiva and those with inflamed gingiva (periodontitis). The main question it aims to answer is:

Is the JAK1/2 pathway overactivated in periodontitis compared to health?

A secondary outcome will be to describe the histological areas, such as epithelium or lamina propria, where the JAK1/2 pathway will be activated including the different subpopulation of cells.

The protocol include one visit where the gingival biopsies are taken.

Participants with healthy gingiva and periodontitis will donate gingival tissue to study the JAK1/2 pathway. All participants will receive diagnosis and treatment of the gingival condition.

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Chile
    • Metropolitan Region
      • Santiago, Metropolitan Region, Chile
        • Recruiting
        • Faculty of Dentistry, University of Chile
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Adults from the northern area of Santiago, Chile

Description

Inclusion Criteria:

  • Adults
  • Sistemically healthy

Exclusion Criteria:

  • Active Maliganancy
  • History of radiation to the head-neck region
  • Chemotherapy or radiation within the last 5 years
  • History of hepatitis B/C or HIV infection
  • Autoimmune diseases
  • Diagnosis of diabetes
  • Pregnancy or lactation
  • More than 3 hospitalizations over the last 3 years
  • Use of systemic antibiotics over the last 3 months
  • Use of systemic corticosteroids or immunosuppressants over the last 3 months
  • Use of cytokine therapy over the last 3 months
  • Use of large doses of pre/probiotic supplements over the last 3 months
  • Smoke more than 10 cigarettes per day

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Healthy gingiva
Adults without gingival inflammation diagnosed by a clinical exam
Periodontits
Adults with periodontitis diagnosed by a clinical exam

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
JAK1/2 pathway activation in gingival tissues
Time Frame: Day 1

The activation of the JAK1/2 pathway will be evaluated by the phophorilation of JAK1/2 in the gingival tissues determined by western blot. Patients will be categorizied as 0, 1, 2.

0 = no phosphorilation

  1. = mild phosphorilation
  2. = intense phosphorilation
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Chile

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2023

Primary Completion (Estimated)

March 31, 2027

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

March 19, 2026

First Submitted That Met QC Criteria

April 10, 2026

First Posted (Actual)

April 17, 2026

Study Record Updates

Last Update Posted (Actual)

April 17, 2026

Last Update Submitted That Met QC Criteria

April 10, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023/11
  • 1231350 (Other Grant/Funding Number: FONDECYT-Research and Development National Agency from the Chilean Government)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Periodontitis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe